FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company is bringing precision therapies for gynaecological cancers
The company has improved access to quality healthcare for seniors across both urban and rural areas
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The facility will be positioned as a Centre of Excellence for tertiary care services
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Subscribe To Our Newsletter & Stay Updated